Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino- 5-ethylpyrrolo[2,3-d]pyrimidines as antifolates

Journal of Medicinal Chemistry

Volumn 50, Issue 13, 2007, Pages 3046-3053

  Gangjee, Aleem ^a   Zeng, Yibin ^a,e   Talreja, Tina ^a   McGuire, John J ^b   Kisliuk, Roy L ^c   Queener, Sherry F ^d  

^a DUQUESNE UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY   (United States)

^e ChemoCentryx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(2,4 DIAMINO 5 ETHYL 7H PYRROLO[2,3 D]PYRIMIDIN 6 YL)SULFANYL]BENZOIC ACID; 5 ETHYL 6 (1 NAPHTHYLSULFANYL) 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE; 5 ETHYL 6 (2 NAPHTHYLSULFANYL) 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE; 5 ETHYL 6 (8 QUINOLINYLSULFANYL) 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE; 5 ETHYL 6 (PHENYLSULFANYL) 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE; 5 ETHYL 6 [(3 METHOXYPHENYL)SULFANYL] 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE; 5 ETHYL 6 [(4 METHOXYPHENYL)SULFANYL] 7 H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE; 5 ETHYL 6 [(4 NITROPHENYL)SULFANYL] 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE; 6 [(2,4 DICHLOROPHENYL)SULFANYL] 5 ETHYL 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE; 6 [(2,5 DIMETHOXYPHENYL)SULFANYL] 5 ETHYL 7H PYRROLO[2,3 D] PYRIMIDINE 2,4 DIAMINE; 6 [(2,6 DICHLOROPHENYL)SULFANYL] 5 ETHYL 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE; 6 [(2,6 DIMETHYLPHENYL)SULFANYL] 5 ETHYL 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE; 6 [(3 CHLOROPHENYL)SULFANYL] 5 ETHYL 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE; 6 [(3,4 DICHLOROPHENYL)SULFANYL] 5 ETHYL 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE; 6 [(4 BROMOPHENYL)SULFANYL] 5 ETHYL 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE; 6 [(4 CHLOROPHENYL)SULFANYL] 5 ETHYL 7H PYRROLO[2,3 D]PYRIMIDINE 2,4 DIAMINE; 6 THIO 2,4 DIAMINO 5 ETHYLPYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; DIHYDROFOLATE REDUCTASE INHIBITOR; FOLIC ACID ANTAGONIST; METHOTREXATE; N [4 [(2,4 DIAMINO 5 ETHYL 7H PYRROLO[2,3 D]PYRIMIDIN 6 YL)SULFANYL]BENZOYL]GLUTAMIC ACID; N [4 [(5 ETHYL 2 AMINO 3,4 DIHYDRO 4 OXO 7H PYRROLO[2,3 D]PYRIMIDIN 6 YL)THIO]BENZOYL]GLUTAMATE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ADDITION REACTION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IMMUNOCOMPROMISED PATIENT; MYCOBACTERIUM AVIUM; NONHUMAN; OPPORTUNISTIC INFECTION; SAPONIFICATION; TOXOPLASMA GONDII;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ESCHERICHIA COLI; FOLIC ACID ANTAGONISTS; HUMANS; MODELS, MOLECULAR; MYCOBACTERIUM AVIUM; PNEUMOCYSTIS CARINII; PYRIMIDINES; PYRROLES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE; TOXOPLASMA;

EID: 34347248076     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070165j     Document Type: Article

References (21)

1. Berman, E. M.; Werbel, L. M. The Renewed Potential for Folate Antagonists in Contemporary Cancer Chemotherapy. J. Med. Chem. 1991, 34, 479-485.
2. Rosowsky, A. Chemistry and Biological Activity of Antifolates. In Progress in Medicinal Chemistry; Ellis, G. P., West, G. B., Eds.; Elsevier Science Publishers: Amsterdam, 1989; pp 1-252.
3. Gangjee, A.; Elzein, E.; Kothare, M.; Vasudevan, A. Classical and Nonclassical Antifolates as Potential Antitumor, Antipneumocystis and Antitoxoplasma Agents. Curr. Pharm. Des. 1996, 2, 263-280.
4. Gangjee, A.; Lin, X.; Kisliuk, R. L.; McGuire, J. J. Synthesis of N-{4-[(2,4-Diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d] pyrimidin-6-yl)thio]benzoyl}-L-glutamic Acid and N-{4-[(2-Amino- 4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio] benzoyl}-L-glutamic Acid as Dual Inhibitors of Dihydrofolate Reductase and Thymidylate Synthase and as Potential Antitumor Agents. J. Med. Chem. 2005, 48, 7215-7222.
5. We thank the Developmental Therapeutics Program of the National Cancer Institute for performing the in vitro anticancer evaluation.
6. Tripos Inc., 1699 South Handley Rd, Suite 303, St. Louis, MO 63144.
7. Piper, J. R.; McCaleb, G. S.; Montgomery, J. A.; Kisliuk, R. L.; Gaumont, Y.; Sirotnak, F. M. Synthesis and Antifolate Activity of 5-Methyl-5-deaza Analogs of Aminopterin, MTX, Folic Acid, and N10-Methyl Folic Acid. J. Med. Chem. 1986, 29, 1080-1087.
8. Hynes, J. B.; Harmon, S. J.; Floyd, G. G.; Farrington, M.; Hart, L. D.; Gale, G. R.; Washtein, W. L.; Sustern, S. S.; Freisheim, J. H. Chemistry and Antitumor Evaluation of Selected Classical 2,4-Diaminoquinazoline Analogues of Folic Acid. J. Med. Chem. 1985, 28, 209-215.
9. Zhao, R.; Goldman, I. D. Resistance to Antifolates. Oncogene 2003, 22, 7431-7457.
10. Werbel, L. M. In Folate Antagonists as Therapeutic Agents; Sirotnak, F. M., Burchall, J. J., Ensminger, W., Montgomery, J. A., Eds.; Academic Press: Orlando, FL, 1984; Vol. 1, pp 261.
11. Klepser, M. E.; Klepser, T. B. Drug Treatment of HIV-Related Opportunistic Infections. Drugs 1997, 53, 40-73.
12. Gangjee, A.; Lin, X.; Queener, S. F. Design, Synthesis, and Biological Evaluation of 2,4-Diamino-5-methyl-6-substituted-pyrrolo[2,3-d] pyrimidines as Dihydrofolate Reductase Inhibitors. J. Med. Chem. 2004, 47, 3689-3692.
13. Gangjee, A.; Mavandadi, F.; Kisliuk, R. L.; McGuire, J. J.; Queener, S. F. 2-Amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines as Non-classical Antifolate Inhibitors of Thymidylate Synthase. J. Med. Chem. 1996, 39, 4563-4568.
14. Taylor, E. C.; Patel, H. H.; Jun, J.-G. A One-Step Ring Transformation/Ring Annulation Approach to Pyrrolo[2,3-d]pyrimidines. A New Synthesis of the Potent Dihydrofolate Reductase Inhibitor TNP-351. J. Org. Chem. 1995, 60, 6684-6687.
15. Gangjee, A.; Zeng, Y.; McGuire, J. J.; Kisliuk, R. L. Synthesis of N-[4-[1-Ethyl-2-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)ethyl]benzoyl] -L-glutamic Acid as an Antifolate. J. Med. Chem. 2002, 45, 1942-1948.
16. Mini, E.; Srimatkandata, S.; Medina, W. D.; Moroson, B. A.; Carman, M. D.; Bertino, J. R. Molecular and Karyological Analysis of Methotrexate-Resistant and - Sensitive Human Leukemic CCRF-CEM Cells. Cancer Res. 1985, 45, 317-325.
17. Rosowsky, A.; Lazarus, H.; Yuan, G. C.; Beltz, W. R.; Mangini, L.; Abelson, H. T.; Modest, E. J.; Frei, E., III. Effects of Methotrexate Esters and Other Lipophilic Antifolates on Methotrexate-Resistant Human Leukemic Lymphoblasts. Biochem. Pharmacol. 1980, 29, 648-652.
18. McCloskey, D. E.; McGuire, J. J.; Russell, C. A.; Rowan, B. G.; Bertino, J. R.; Pizzorno, G.; Mini, E. Decreased Folylpolyglutamate Synthetase Activity as a Mechanism of Methotrexate Resistance in CCRF-CEM Human Leukemia Sublines. J. Biol. Chem. 1991, 266, 6181-6187.
19. Hakala, M. T.; Taylor, E. The Ability of Purine and Thymidine Derivatives and of Glycine to Support the Growth of Mammalian Cells in Culture. J. Biol. Chem. 1959, 234, 126-128.
20. Grindey, G. B.; Wang, M. C.; Kinahan, J. J. Thymidine Induced Perturbations in Ribonucleoside and Deoxyribonucleoside Triphosphate Pools in Human Leukemic CCRF-CEM Cells. Mol. Pharmacol. 1979, 16, 601-606.
21. Foley, G. F.; Lazarus, H.; Farber, S.; Uzman, B. G.; Boone, B. A.; McCarthy, R. E. Continuous Culture of Lymphoblasts from Peripheral Blood of a Child with Acute Leukemia. Cancer 1965, 18, 522-529.